Table 2—

FMD at baseline and at end of the DAL1 study

PlaceboA10A80
n444643
Diameter (mm)
 Baseline4.88 ± 0.134.89 ± 0.104.77 ± 0.09
 30 weeks4.81 ± 0.114.87 ± 0.094.89 ± 0.09
FMD (%)
 Baseline2.88 ± 0.653.41 ± 0.563.18 ± 0.35
 30 weeks3.41 ± 0.463.20 ± 0.483.10 ± 0.42
NTG (%)
 Baseline6.90 ± 1.06.80 ± 0.896.01 ± 0.88
 30 weeks7.74 ± 0.536.87 ± 0.686.59 ± 0.86
  • Data are means ± SE.